Latest news

PCI Biotech: Fourth quarter and preliminary full year 2015 results

Posted on Feb 9, 2016

Oslo, 9 February 2016. Please find enclosed the financial report and presentation for fourth quarter 2015. A presentation will be held today, Tuesday 9 February 2016, at Oslo Cancer Cluster Innovation Park. Time: Tuesday February 9, 09.00-10.00 hrs. Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. 1602 […]

PCI Biotech and Ultimovacs initiates preclinical research collaboration

Posted on Jan 27, 2016

Oslo, 27 January 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are initiating a preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies. The partnership is governed […]

Dose escalation in the bile duct cancer study completed with promising early signs of efficacy

Posted on Jan 22, 2016

Oslo, 22 January 2016 – PCI Biotech (PCIB) reported today that the treatment evaluation of the fourth dose cohort in the Phase I/II study of fimaporfin (Amphinex®) in patients with inoperable bile duct cancer has been completed.  The   Cohort   Review   Committee   (CRC)   of clinical experts and company representatives has recommended that the study progress into […]